Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jul 16, 2024 11:52am
206 Views
Post# 36134823

Still in silent mode...

Still in silent mode...Merger approved.
Directors now approved with the exception of Dennis Turpin.
Peter Edwards didn't stand for re-election.
New company name now approved.

There was no overview of the past year by Ronnie and Gilles like last year and no plan presented or status update on anything. Still in silent mode. Last year AEZS presented its Q2 financials on August 9. 

With the new name approved I guess they will apply immediately to get the name of the stock changed and the symbol. They can now update the website and PR material with the new branding. It would seem a presentation on the new company could take place with the new plan and new branding. 

Top-line and full diagnostic trial data is scheduled for Q3 and top-line data could be imminent given the timeline to presentation of adult data previously. That data and a potential licensing deal could greatly affect the forward plan given the potential upfront money, etc.
 
Then there's all the expected events lined up as has been discussed: bam, bam, bam... 

The S&P Biotech ETF is essentially at its 2 1/2 year high.
<< Previous
Bullboard Posts
Next >>